Your English writing platform
Discover LudwigSuggestions(5)
Exact(6)
Thirty patients (46.9%) experienced stabilisation of disease, with a rate of overall clinical benefit (complete responses, partial responses, and stabilisation of disease) of 85.9%.
Four patients experienced stabilisation of their disease (melanoma, cervical cancer and parotid cancer) for a median duration of 12 weeks (range 12 30 weeks).
Seven patients with previously rapidly progressive metastatic tumours experienced stabilisation of disease while receiving GM-CSF and one patient with a previously heavily pretreated metastatic soft tissue sarcoma underwent a greater than 50% reduction of tumour volume.
One patient with a soft tissue sarcoma and one with renal cell cancer, treated at the 160 and 140 mg m−2 dose level, respectively, experienced stabilisation of disease during six and eight cycles.
Fifty (29.9%) patients treated with FOLFIRI-Bev and 52 (31.3%) patients treated with CAPIRI-Bev experienced stabilisation of disease, whereas 41 (24.6%) and 48 (28.9%) patients, respectively, had progression of their disease at the first efficacy evaluation.
When the T cells were infused with IL-2 only, 6 out of 10 patients experienced stabilisation of the disease whereas the infusion of the cells with both IL-2 and zoledronate resulted in 5 out of 10 disease stabilisations and 1 complete response.
Similar(54)
In this study, 30 patients received aflibercept 6 mg kg−1 plus docetaxel, 4 experienced PRs (13.3%), and 17 had SD (56.7%), with 12 patients (40.0%) experiencing stabilisation >3 months.
Evidence from early clinical studies showed that cancer patients receiving fish oil supplements experienced weight stabilisation or gained weight.
One patient experienced a stabilisation of his disease.
A further two patients experienced disease stabilisation at the recommended dose.
An additional 56% experienced disease stabilisation and overall median survival was 8 months.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com